VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q59175077 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241221010841.0
008 241221nneanz||abbn n and d
035 ‎‡a (WKP)Q59175077‏
024 ‎‡a 0000-0002-2562-1415‏ ‎‡2 orcid‏
035 ‎‡a (OCoLC)Q59175077‏
100 0 ‎‡a Juan Domínguez-Herrera‏ ‎‡c researcher ORCID ID = 0000-0002-2562-1415‏ ‎‡9 en‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a Juan Domínguez-Herrera‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's Attenuated virulence of a slow-growing pandrug-resistant Acinetobacter baumannii is associated with decreased expression of genes encoding the porins CarO and OprD-like‏
670 ‎‡a Author's Colistin resistance in a clinical Acinetobacter baumannii strain appearing after colistin treatment: effect on virulence and bacterial fitness.‏
670 ‎‡a Author's Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli.‏
670 ‎‡a Author's Efficacy of ceftaroline versus vancomycin in an experimental foreign-body and systemic infection model caused by biofilm-producing methicillin-resistant Staphylococcus epidermidis‏
670 ‎‡a Author's Efficacy of daptomycin versus vancomycin in an experimental model of foreign-body and systemic infection caused by biofilm producers and methicillin-resistant Staphylococcus epidermidis‏
670 ‎‡a Author's Efficacy of linezolid versus a pharmacodynamically optimized vancomycin therapy in an experimental pneumonia model caused by methicillin-resistant Staphylococcus aureus.‏
670 ‎‡a Author's Impact of qnrA1, qnrB1 and qnrS1 on the efficacy of ciprofloxacin and levofloxacin in an experimental pneumonia model caused by Escherichia coli with or without the GyrA mutation Ser83Leu.‏
670 ‎‡a Author's Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii.‏
670 ‎‡a Author's In vitro activity and in vivo efficacy of clavulanic acid against Acinetobacter baumannii.‏
670 ‎‡a Author's In vitro and in vivo reduced fitness and virulence in ciprofloxacin-resistant Acinetobacter baumannii.‏
670 ‎‡a Author's In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.‏
670 ‎‡a Author's Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.‏
670 ‎‡a Author's Platelet-activating factor receptor initiates contact of Acinetobacter baumannii expressing phosphorylcholine with host cells.‏
670 ‎‡a Author's Pre-clinical studies of a new quinolone‏
670 ‎‡a Author's Pre-clinical studies of a new quinolone (UB-8902) against Acinetobacter baumannii resistant to ciprofloxacin‏
670 ‎‡a Author's Rapid detection of antibiotic resistance in Acinetobacter baumannii using quantitative real-time PCR.‏
670 ‎‡a Author's Rifampin protects human lung epithelial cells against cytotoxicity induced by clinical multi and pandrug-resistant Acinetobacter baumannii.‏
670 ‎‡a Author's Therapeutic efficacy of lysophosphatidylcholine in severe infections caused by Acinetobacter baumannii.‏
670 ‎‡a Author's Vaccination with Outer Membrane Complexes Elicits Rapid Protective Immunity to Multidrug-Resistant Acinetobacter baumannii‏
909 ‎‡a (orcid) 0000000225621415‏ ‎‡9 1‏
919 ‎‡a impairedvirulenceandinvivofitnessofcolistinresistantacinetobacterbaumannii‏ ‎‡A Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii.‏ ‎‡9 1‏
919 ‎‡a invitroactivityandinvivoefficacyofclavulanicacidagainstacinetobacterbaumannii‏ ‎‡A In vitro activity and in vivo efficacy of clavulanic acid against Acinetobacter baumannii.‏ ‎‡9 1‏
919 ‎‡a invitroandinvivoreducedfitnessandvirulenceinciprofloxacinresistantacinetobacterbaumannii‏ ‎‡A In vitro and in vivo reduced fitness and virulence in ciprofloxacin-resistant Acinetobacter baumannii.‏ ‎‡9 1‏
919 ‎‡a invitroeffectofqnra1qnrb1andqnrs1genesonfluoroquinoloneactivityagainstisogenicescherichiacoliisolateswithmutationsingyraandparc‏ ‎‡A In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.‏ ‎‡9 1‏
919 ‎‡a inoculumeffectontheefficaciesofamoxicillinclavulanatepiperacillintazobactamandimipenemagainstextendedspectrumβlactamaseesblproducingandnonesblproducingescherichiacoliinanexperimentalmurinesepsismodel‏ ‎‡A Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.‏ ‎‡9 1‏
919 ‎‡a plateletactivatingfactorreceptorinitiatescontactofacinetobacterbaumanniiexpressingphosphorylcholinewithhostcells‏ ‎‡A Platelet-activating factor receptor initiates contact of Acinetobacter baumannii expressing phosphorylcholine with host cells.‏ ‎‡9 1‏
919 ‎‡a preclinicalstudiesofanewquinolone‏ ‎‡A Pre-clinical studies of a new quinolone‏ ‎‡9 1‏
919 ‎‡a preclinicalstudiesofanewquinoloneub8902againstacinetobacterbaumanniiresistanttociprofloxacin‏ ‎‡A Pre-clinical studies of a new quinolone (UB-8902) against Acinetobacter baumannii resistant to ciprofloxacin‏ ‎‡9 1‏
919 ‎‡a rapiddetectionofantibioticresistanceinacinetobacterbaumanniiusingquantitativerealtimepcr‏ ‎‡A Rapid detection of antibiotic resistance in Acinetobacter baumannii using quantitative real-time PCR.‏ ‎‡9 1‏
919 ‎‡a rifampinprotectshumanlungepithelialcellsagainstcytotoxicityinducedbyclinicalmultiandpandrugresistantacinetobacterbaumannii‏ ‎‡A Rifampin protects human lung epithelial cells against cytotoxicity induced by clinical multi and pandrug-resistant Acinetobacter baumannii.‏ ‎‡9 1‏
919 ‎‡a therapeuticefficacyoflysophosphatidylcholineinsevereinfectionscausedbyacinetobacterbaumannii‏ ‎‡A Therapeutic efficacy of lysophosphatidylcholine in severe infections caused by Acinetobacter baumannii.‏ ‎‡9 1‏
919 ‎‡a vaccinationwithoutermembranecomplexeselicitsrapidprotectiveimmunitytomultidrugresistantacinetobacterbaumannii‏ ‎‡A Vaccination with Outer Membrane Complexes Elicits Rapid Protective Immunity to Multidrug-Resistant Acinetobacter baumannii‏ ‎‡9 1‏
919 ‎‡a attenuatedvirulenceofaslowgrowingpandrugresistantacinetobacterbaumanniiisassociatedwithdecreasedexpressionofgenesencodingtheporinscaroandoprdlike‏ ‎‡A Attenuated virulence of a slow-growing pandrug-resistant Acinetobacter baumannii is associated with decreased expression of genes encoding the porins CarO and OprD-like‏ ‎‡9 1‏
919 ‎‡a colistinresistanceinaclinicalacinetobacterbaumanniistrainappearingaftercolistintreatmenteffectonvirulenceandbacterialfitness‏ ‎‡A Colistin resistance in a clinical Acinetobacter baumannii strain appearing after colistin treatment: effect on virulence and bacterial fitness.‏ ‎‡9 1‏
919 ‎‡a efficaciesofcolistinandtigecyclineinmicewithexperimentalpneumoniaduetondm1producingstrainsofklebsiellapneumoniaeandescherichiacoli‏ ‎‡A Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli.‏ ‎‡9 1‏
919 ‎‡a efficacyofceftarolineversusvancomycininanexperimentalforeignbodyandsystemicinfectionmodelcausedbybiofilmproducingmethicillinresistantstaphylococcusepidermidis‏ ‎‡A Efficacy of ceftaroline versus vancomycin in an experimental foreign-body and systemic infection model caused by biofilm-producing methicillin-resistant Staphylococcus epidermidis‏ ‎‡9 1‏
919 ‎‡a efficacyofdaptomycinversusvancomycininanexperimentalmodelofforeignbodyandsystemicinfectioncausedbybiofilmproducersandmethicillinresistantstaphylococcusepidermidis‏ ‎‡A Efficacy of daptomycin versus vancomycin in an experimental model of foreign-body and systemic infection caused by biofilm producers and methicillin-resistant Staphylococcus epidermidis‏ ‎‡9 1‏
919 ‎‡a efficacyoflinezolidversusapharmacodynamicallyoptimizedvancomycintherapyinanexperimentalpneumoniamodelcausedbymethicillinresistantstaphylococcusaureus‏ ‎‡A Efficacy of linezolid versus a pharmacodynamically optimized vancomycin therapy in an experimental pneumonia model caused by methicillin-resistant Staphylococcus aureus.‏ ‎‡9 1‏
919 ‎‡a impactofqnra1qnrb1andqnrs1ontheefficacyofciprofloxacinandlevofloxacininanexperimentalpneumoniamodelcausedbyescherichiacoliwithorwithoutthegyramutationser83leu‏ ‎‡A Impact of qnrA1, qnrB1 and qnrS1 on the efficacy of ciprofloxacin and levofloxacin in an experimental pneumonia model caused by Escherichia coli with or without the GyrA mutation Ser83Leu.‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 SUDOC|259942537
996 ‎‡2 LC|n 2008029566
996 ‎‡2 BNE|XX1000553
996 ‎‡2 LC|n 2018070772
996 ‎‡2 DNB|1056428066
996 ‎‡2 LC|n 2024010561
996 ‎‡2 ISNI|0000000376142243
996 ‎‡2 BAV|495_218507
996 ‎‡2 LC|n 96114533
996 ‎‡2 LC|no2009049011
996 ‎‡2 BNE|XX1549245
996 ‎‡2 BNCHL|10000000000000000036005
996 ‎‡2 LC|n 90669620
996 ‎‡2 ISNI|0000000081624798
996 ‎‡2 BNCHL|10000000000000000061389
996 ‎‡2 BNE|XX899518
996 ‎‡2 DNB|1066234736
996 ‎‡2 RERO|A003200574
996 ‎‡2 BNF|17731441
996 ‎‡2 BNE|XX964490
996 ‎‡2 BIBSYS|90283943
996 ‎‡2 BNE|XX4960101
996 ‎‡2 SZ|1312096004
996 ‎‡2 BAV|495_117452
996 ‎‡2 ISNI|0000000067548557
996 ‎‡2 BNE|XX969518
996 ‎‡2 DNB|1054444978
996 ‎‡2 DNB|134104811
996 ‎‡2 BNF|12963784
996 ‎‡2 BNE|XX1145497
996 ‎‡2 SUDOC|052500950
996 ‎‡2 LC|n 96105086
996 ‎‡2 LC|n 2023000460
996 ‎‡2 ISNI|0000000066361993
996 ‎‡2 CAOONL|ncf10924472
996 ‎‡2 ISNI|0000000060408914
996 ‎‡2 BNCHL|10000000000000000850436
996 ‎‡2 DNB|1057322350
996 ‎‡2 SUDOC|189942592
996 ‎‡2 LC|no 96031334
996 ‎‡2 BNCHL|10000000000000000840144
996 ‎‡2 DNB|1056544244
996 ‎‡2 NLA|000035066614
996 ‎‡2 ISNI|000000003510648X
996 ‎‡2 PLWABN|9810652653905606
996 ‎‡2 BNCHL|10000000000000000837289
996 ‎‡2 DNB|1057052078
996 ‎‡2 BNE|XX1008950
996 ‎‡2 ISNI|0000000060286814
996 ‎‡2 LC|no2008000907
996 ‎‡2 BNE|XX5648502
996 ‎‡2 ISNI|0000000079979514
996 ‎‡2 BNF|17803678
996 ‎‡2 NTA|32652164X
996 ‎‡2 DNB|1221633848
996 ‎‡2 BNCHL|10000000000000000847156
996 ‎‡2 DNB|1227757654
996 ‎‡2 RERO|A003530949
996 ‎‡2 ISNI|000000011546288X
996 ‎‡2 LC|n 80066726
996 ‎‡2 DNB|138534527
996 ‎‡2 SUDOC|169550575
996 ‎‡2 ISNI|0000000059425995
996 ‎‡2 BAV|495_364698
996 ‎‡2 BNE|XX1643430
996 ‎‡2 LC|no2017044580
996 ‎‡2 SUDOC|176680055
996 ‎‡2 BNC|981058511000406706
996 ‎‡2 LC|no2011167988
996 ‎‡2 LC|no2022008979
996 ‎‡2 NTA|126044597
996 ‎‡2 J9U|987007312182005171
996 ‎‡2 LC|nr 00006306
996 ‎‡2 BNE|XX5163372
996 ‎‡2 BNE|XX909507
996 ‎‡2 LC|no2012105350
996 ‎‡2 DNB|1237278309
996 ‎‡2 LC|no2017014418
996 ‎‡2 BNF|16916982
996 ‎‡2 DNB|132883643
996 ‎‡2 LC|n 2018030732
996 ‎‡2 DNB|133578275
996 ‎‡2 ARBABN|000047108
996 ‎‡2 BNE|XX1603825
996 ‎‡2 LC|ns2014005662
996 ‎‡2 BIBSYS|13064238
996 ‎‡2 SUDOC|166482161
996 ‎‡2 NUKAT|n 2003023817
996 ‎‡2 BNF|17010504
996 ‎‡2 ISNI|000000010766342X
996 ‎‡2 DNB|173874584
996 ‎‡2 BIBSYS|90702704
996 ‎‡2 LC|n 86072639
996 ‎‡2 SUDOC|236918648
996 ‎‡2 BNCHL|10000000000000000024125
996 ‎‡2 BNF|14643994
996 ‎‡2 LC|no 96009288
996 ‎‡2 BNE|XX1397663
996 ‎‡2 SUDOC|233591419
996 ‎‡2 DNB|131666037
996 ‎‡2 CAOONL|ncf10674646
996 ‎‡2 SUDOC|266748422
996 ‎‡2 ISNI|0000000042143596
996 ‎‡2 LC|no2011081498
996 ‎‡2 VLACC|000044959
996 ‎‡2 DNB|1052207081
996 ‎‡2 SUDOC|133059154
996 ‎‡2 LC|no2014130185
996 ‎‡2 LC|no2022030652
996 ‎‡2 SUDOC|22614321X
996 ‎‡2 ISNI|0000000026458424
996 ‎‡2 NII|DA09470557
996 ‎‡2 LC|n 79033227
996 ‎‡2 BNF|16588787
996 ‎‡2 BNE|XX1000411
996 ‎‡2 DNB|1298277094
996 ‎‡2 BNE|XX884683
996 ‎‡2 BNE|XX1304739
996 ‎‡2 ISNI|0000000116655173
996 ‎‡2 RERO|A003366900
996 ‎‡2 RERO|A003366901
996 ‎‡2 BNC|981058509530006706
996 ‎‡2 CAOONL|ncf11430771
996 ‎‡2 PTBNP|1228575
996 ‎‡2 ISNI|000000043178950X
996 ‎‡2 ISNI|000000006708756X
996 ‎‡2 SUDOC|088842355
996 ‎‡2 ISNI|0000000043348833
996 ‎‡2 BNCHL|10000000000000000126939
996 ‎‡2 BNF|17965332
996 ‎‡2 SUDOC|169849511
996 ‎‡2 LC|ns2012005035
996 ‎‡2 BNCHL|10000000000000000183758
996 ‎‡2 BNE|XX4811573
996 ‎‡2 ISNI|0000000449191696
996 ‎‡2 ISNI|0000000031673524
996 ‎‡2 ISNI|0000000419160362
996 ‎‡2 BNCHL|10000000000000000126313
996 ‎‡2 LC|n 2001061467
996 ‎‡2 BNE|XX852682
996 ‎‡2 SUDOC|190602228
996 ‎‡2 LC|ns2018002601
996 ‎‡2 SUDOC|095199950
996 ‎‡2 ISNI|0000000118451107
996 ‎‡2 BNE|XX1160187
996 ‎‡2 BAV|495_1385
996 ‎‡2 BAV|495_1384
996 ‎‡2 ISNI|0000000023792873
996 ‎‡2 LC|ns2016004437
996 ‎‡2 BNE|XX5033874
996 ‎‡2 J9U|987007390657905171
996 ‎‡2 LC|ns2012000965
996 ‎‡2 LC|no2009055956
996 ‎‡2 LC|n 81059249
996 ‎‡2 CAOONL|ncf10715546
996 ‎‡2 LC|no2010128948
996 ‎‡2 LC|no2021045812
996 ‎‡2 NYNYRILM|12465
996 ‎‡2 LC|n 2013036902
996 ‎‡2 SUDOC|079032885
996 ‎‡2 BNE|XX1778330
996 ‎‡2 ISNI|0000000085411984
996 ‎‡2 BNE|XX1008417
996 ‎‡2 DNB|116745517
996 ‎‡2 SUDOC|089439163
996 ‎‡2 BNE|XX4890170
996 ‎‡2 ISNI|0000000437221878
996 ‎‡2 BNCHL|10000000000000000110208
996 ‎‡2 SUDOC|147103568
996 ‎‡2 LC|n 86843380
996 ‎‡2 DNB|1157836070
996 ‎‡2 SUDOC|034739874
996 ‎‡2 LC|no2010191551
996 ‎‡2 LC|n 2010062571
996 ‎‡2 BNCHL|10000000000000000240248
996 ‎‡2 LC|n 85333154
996 ‎‡2 DNB|1056207914
996 ‎‡2 ISNI|0000000083758159
996 ‎‡2 LC|no2007021951
996 ‎‡2 BNCHL|10000000000000000213566
996 ‎‡2 DNB|143245147
996 ‎‡2 LC|no2008041348
996 ‎‡2 LC|no2017065767
996 ‎‡2 BNE|XX1524633
996 ‎‡2 DNB|1019407409
996 ‎‡2 NUKAT|n 2011106148
996 ‎‡2 BNE|XX1541334
996 ‎‡2 SUDOC|027783588
996 ‎‡2 J9U|987007314867005171
996 ‎‡2 BAV|495_360692
996 ‎‡2 LC|no2003128359
996 ‎‡2 LC|no2002097352
996 ‎‡2 LC|n 2007036512
996 ‎‡2 LC|no2010127872
996 ‎‡2 LC|no2002071510
996 ‎‡2 CAOONL|ncf10702084
996 ‎‡2 BNCHL|10000000000000000023931
996 ‎‡2 LC|no2008034495
996 ‎‡2 BNCHL|10000000000000000274003
996 ‎‡2 BNC|981058515539506706
996 ‎‡2 LC|nr2001040047
996 ‎‡2 NUKAT|n 2019221655
996 ‎‡2 LC|ns2021000965
996 ‎‡2 LC|no 91017216
996 ‎‡2 ISNI|0000000114623215
996 ‎‡2 LC|no2008001706
996 ‎‡2 CAOONL|ncf13711866
996 ‎‡2 LC|no2021040778
996 ‎‡2 BNCHL|10000000000000000126445
996 ‎‡2 ISNI|0000000051241067
996 ‎‡2 NUKAT|n 2016137957
996 ‎‡2 BNE|XX5248385
996 ‎‡2 ISNI|0000000451657176
996 ‎‡2 LC|n 82012607
996 ‎‡2 JPG|500015923
996 ‎‡2 BNE|XX1511565
996 ‎‡2 BNCHL|10000000000000000008602
996 ‎‡2 ISNI|0000000359594539
996 ‎‡2 LC|no2018000032
996 ‎‡2 RERO|A027565655
996 ‎‡2 LC|no2021107126
996 ‎‡2 J9U|987007436018905171
996 ‎‡2 DNB|118800388
996 ‎‡2 BNE|XX1316725
996 ‎‡2 ISNI|000000003174082X
996 ‎‡2 ISNI|0000000393917987
996 ‎‡2 ISNI|0000000121177161
996 ‎‡2 NLA|000057817838
996 ‎‡2 NII|DA11548737
996 ‎‡2 ISNI|0000000049997084
996 ‎‡2 BNE|XX1304618
996 ‎‡2 LC|no 96034156
996 ‎‡2 SUDOC|147220483
996 ‎‡2 ISNI|0000000475369638
996 ‎‡2 NTA|085028401
996 ‎‡2 BNE|XX5019681
996 ‎‡2 LC|nr 96002446
996 ‎‡2 NII|DA12431713
996 ‎‡2 BNE|XX1711927
996 ‎‡2 BNE|XX5078138
996 ‎‡2 BNCHL|10000000000000000142387
996 ‎‡2 ISNI|0000000097197698
996 ‎‡2 BNCHL|10000000000000000868448
996 ‎‡2 BNCHL|10000000000000000098266
996 ‎‡2 BNE|XX1612119
996 ‎‡2 LC|no2017140767
996 ‎‡2 LC|n 85366725
996 ‎‡2 ARBABN|000047168
996 ‎‡2 BNCHL|10000000000000000860604
996 ‎‡2 BNE|XX1000678
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏